Xiaopeng Tian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiaopeng Tian has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Depei Wu
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China
1 shared publication - Dongpeng Jiang
Institute of Blood and Marrow Transplantation, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
1 shared publication - Fengtao You
PersonGen BioTherapeutics (Suzhou) Co., Ltd. Suzhou China
1 shared publication - Gangli An
Cyrus Tang Medical Institute, Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou 215123, China
1 shared publication - Hai Wu
PersonGen BioTherapeutics (Suzhou) Co., Ltd. Suzhou China
1 shared publication Haiwen Huang
Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
1 shared publication
Latest Publications
- Open Access
- 6 September 2023
- Published by Wiley in European Journal of Haematology
- Vol. 112 (1) , 64-74
Enhanced efficacy of CD19/CD22 bispecific CAR‐T cells with EAAAK linker on B‐cell malignancies
Objectives: Despite the great success of CD19 CAR‐T cell therapy, its clinical efficacy has been greatly hampered by the high relapse rate. In this study, we designed and compared four structures of CD19/CD22 bispecific CAR‐T cells with different linkers and different orders of the antibody sequences.Methods: We detected the cytotoxicity, cytokine secretion levels, sustainable killing ability, differentiation, exhaustion of these four CAR‐T cells in vitro. The optimal Bis‐C CAR‐T cells were evaluated the efficacy using NSG mice.Results: The two structures of CD19/CD22 bispecific CAR‐T cells using (EAAAK)3 as linker had more significant cytotoxicity and cytokine secretion levels. In the process of continuous killing, Bis‐C CAR‐T cells showed better sustained killing ability, memory phenotype differentiation, and exhaustion. In the in vivo experiment mimicking CD19‐negative relapse, Bis‐C CAR‐T was more able to control the tumor progression of mice in the CD19 low expression or no expression groups than CD19 CAR‐T.Conclusions: This study has generated a novel bispecific CAR‐T cell that can simultaneously target CD19 or CD22 positive tumor cells, providing a new strategy to address the limitations of single‐targeted CAR‐T therapy in B‐cell tumors (limited response or relapse).
- 6 September 2023
- Published by Wiley in European Journal of Haematology
- Vol. 112 (1) , 64-74
Open AccessEnhanced efficacy of CD19/CD22 bispecific CAR‐T cells with EAAAK linker on B‐cell malignancies
Objectives: Despite the great success of CD19 CAR‐T cell therapy, its clinical efficacy has been greatly hampered by the high relapse rate. In this study, we designed and compared four structures of CD19/CD22 bispecific CAR‐T cells with different linkers and different orders of the antibody sequences.Methods: We detected the cytotoxicity, cytokine secretion levels, sustainable killing ability, differentiation, exhaustion of these four CAR‐T cells in vitro. The optimal Bis‐C CAR‐T cells were evaluated the efficacy using NSG mice.Results: The two structures of CD19/CD22 bispecific CAR‐T cells using (EAAAK)3 as linker had more significant cytotoxicity and cytokine secretion levels. In the process of continuous killing, Bis‐C CAR‐T cells showed better sustained killing ability, memory phenotype differentiation, and exhaustion. In the in vivo experiment mimicking CD19‐negative relapse, Bis‐C CAR‐T was more able to control the tumor progression of mice in the CD19 low expression or no expression groups than CD19 CAR‐T.Conclusions: This study has generated a novel bispecific CAR‐T cell that can simultaneously target CD19 or CD22 positive tumor cells, providing a new strategy to address the limitations of single‐targeted CAR‐T therapy in B‐cell tumors (limited response or relapse).
- Open Access
- 20 June 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-14
Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma
BCMA-targeting chimeric antigen receptor (CAR) T cell therapy demonstrates impressive clinical response in multiple myeloma (MM). However, some patients with BCMA-deficient tumours cannot benefit from this therapy, and others can experience BCMA antigen loss leading to relapse, thus necessitating the identification of additional CAR-T targets. Here, we show that FcRH5 is expressed on multiple myeloma cells and can be targeted with CAR-T cells. FcRH5 CAR-T cells elicited antigen-specific activation, cytokine secretion and cytotoxicity against MM cells. Moreover, FcRH5 CAR-T cells exhibited robust tumoricidal efficacy in murine xenograft models, including one deficient in BCMA expression. We also show that different forms of soluble FcRH5 can interfere with the efficacy of FcRH5 CAR-T cells. Lastly, FcRH5/BCMA-bispecific CAR-T cells efficiently recognized MM cells expressing FcRH5 and/or BCMA and displayed improved efficacy, compared with mono-specific CAR-T cells in vivo. These findings suggest that targeting FcRH5 with CAR-T cells may represent a promising therapeutic avenue for MM.
- 20 June 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-14
Open AccessChimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma
BCMA-targeting chimeric antigen receptor (CAR) T cell therapy demonstrates impressive clinical response in multiple myeloma (MM). However, some patients with BCMA-deficient tumours cannot benefit from this therapy, and others can experience BCMA antigen loss leading to relapse, thus necessitating the identification of additional CAR-T targets. Here, we show that FcRH5 is expressed on multiple myeloma cells and can be targeted with CAR-T cells. FcRH5 CAR-T cells elicited antigen-specific activation, cytokine secretion and cytotoxicity against MM cells. Moreover, FcRH5 CAR-T cells exhibited robust tumoricidal efficacy in murine xenograft models, including one deficient in BCMA expression. We also show that different forms of soluble FcRH5 can interfere with the efficacy of FcRH5 CAR-T cells. Lastly, FcRH5/BCMA-bispecific CAR-T cells efficiently recognized MM cells expressing FcRH5 and/or BCMA and displayed improved efficacy, compared with mono-specific CAR-T cells in vivo. These findings suggest that targeting FcRH5 with CAR-T cells may represent a promising therapeutic avenue for MM.